Skip to main content
Equibles
IOVA logo

IOVA · Iovance Biotherapeutics, Inc.

Track IOVA — free

Use IOVA with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about IOVA

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$6.98 +0.46 (+7.06%) At close · Aug 14
Market Cap
$3.16B
Shares
452.97M

Iovance Biotherapeutics, Inc. Earnings Call Transcripts

Every quarterly earnings call for Iovance Biotherapeutics, Inc. (IOVA) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $238,000 −$106.53M '23 Q2 23-08-08 · $469,000 −$113.76M '23 Q3 23-11-07 · $715,000 −$112.98M '24 Q1 24-05-09 ▲12969.7% $31.11M −$97.10M '24 Q2 24-08-08 ▲12385.1% $58.55M −$83.54M '24 Q3 24-11-07 · $73.69M −$78.56M '24 Q4 25-02-27 ▲6798.5% $49.32M −$116.16M '25 Q1 25-05-08 ▲92.7% $59.95M −$111.66M '25 Q2 25-08-07 ▲15.2% $67.45M −$91.25M '25 Q3 25-11-06 ▲17.7% $86.77M −$71.90M '25 Q4 26-02-24 ▲44.8% $71.43M −$79.05M '26 Q1 26-05-07 LATEST ▲65.7% $99.31M −$47.31M '26 Q2 26-08-06
Earnings call
FY26 · Q2
2026-08-06
Iovance Biotherapeutics, Inc. Q2 FY2026 Earnings Call
Confident tone Demand and sales momentum for AMPAG/AMTAGV Lung 202 trial enrollment and durability Forward guidance update
Revenue
$99.31M
▲ 65.7% YoY
Diluted EPS
$-0.11
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-04
Jefferies Global Healthcare Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-07
Iovance Biotherapeutics, Inc. Q1 FY2026 Earnings Call
Confident tone Amtagvi (lifileucil) commercial growth In-house manufacturing (ICPC) Pipeline expansion across solid tumors
Revenue
$71.43M
▲ 44.8% YoY
Diluted EPS
$-0.19
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-03-11
Barclays 28th Annual Global Healthcare Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-02-24
Iovance Biotherapeutics, Inc. Q4 FY2025 Earnings Call
Confident tone Manufacturing and operations Gross margin improvement Cash runway and financial discipline
Revenue
$86.77M*
▲ 17.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Iovance Biotherapeutics, Inc. Q3 FY2025 Earnings Call
Confident tone Lung Cancer Pipeline (LUN202) Manufacturing Centralization and Margin Improvement Community and Academic ATC Expansion
Revenue
$67.45M
▲ 15.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Iovance Biotherapeutics, Inc. Q2 FY2025 Earnings Call
Positive tone Revenue guidance and growth Manufacturing improvements Strategic restructuring and cost savings
Revenue
$59.95M
▲ 92.7% YoY
Diluted EPS
$-0.33
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Iovance Biotherapeutics, Inc. Q1 FY2025 Earnings Call
Positive tone Amtagvi U.S. commercial launch Proleukin sales dynamics Q1 revenue shortfall and revised guidance
Revenue
$49.32M
▲ 6798.5% YoY
Diluted EPS
$-0.36
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Iovance Biotherapeutics, Inc. Q4 FY2024 Earnings Call
Confident tone Amtagvi commercial launch and uptake Manufacturing capacity and supply Pipeline expansion - frontline melanoma and NSCLC
Revenue
$73.69M*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Iovance Biotherapeutics, Inc. Q3 FY2024 Earnings Call
Confident tone Amtagvi commercial launch and revenue Manufacturing capacity and turnaround Gross margin outlook
Revenue
$58.55M
▲ 12385.1% YoY
Diluted EPS
$-0.28
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Iovance Biotherapeutics, Inc. Q2 FY2024 Earnings Call
Confident tone Amtagvi U.S. Commercial Launch Proleukin Sales and Revenue Mix Pipeline and Label Expansion
Revenue
$31.11M
▲ 12969.7% YoY
Diluted EPS
$-0.34
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Iovance Biotherapeutics, Inc. Q1 FY2024 Earnings Call
Confident tone Amtagvi U.S. Commercial Launch Commercial Manufacturing Capacity ATC Network Expansion
Revenue
$715,000
Diluted EPS
$-0.42
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-28
Iovance Biotherapeutics, Inc. Q4 FY2023 Earnings Call
Confident tone AMTAGVI U.S. Launch Manufacturing Capacity Financial Position
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Iovance Biotherapeutics, Inc. Q3 FY2023 Earnings Call
Revenue
$469,000
Diluted EPS
$-0.46
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Iovance Biotherapeutics, Inc. Q2 FY2023 Earnings Call
Revenue
$238,000
Diluted EPS
$-0.47
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Iovance Biotherapeutics, Inc. Q1 FY2023 Earnings Call
Diluted EPS
$-0.50
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Iovance Biotherapeutics, Inc. Q4 FY2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Iovance Biotherapeutics, Inc. Q3 FY2022 Earnings Call
Diluted EPS
$-0.63
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Iovance Biotherapeutics, Inc. Q2 FY2022 Earnings Call
Diluted EPS
$-0.63
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Iovance Biotherapeutics, Inc. Q1 FY2022 Earnings Call
Diluted EPS
$-0.58
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
Iovance Biotherapeutics, Inc. Q4 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Iovance Biotherapeutics, Inc. Q3 FY2021 Earnings Call
Diluted EPS
$-0.55
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Iovance Biotherapeutics, Inc. Q2 FY2021 Earnings Call
Diluted EPS
$-0.53
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Iovance Biotherapeutics, Inc. Q1 FY2021 Earnings Call
Diluted EPS
$-0.51
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-25
Iovance Biotherapeutics, Inc. Q4 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Iovance Biotherapeutics, Inc. Q3 FY2020 Earnings Call
Diluted EPS
$-0.40
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Iovance Biotherapeutics, Inc. Q2 FY2020 Earnings Call
Diluted EPS
$-0.47
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-05
Iovance Biotherapeutics, Inc. Q1 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-02-25
Iovance Biotherapeutics, Inc. Q4 FY2019 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–29 of 29 earnings calls
Key facts CIK 1425205 CUSIP 462260100 13F (30d) 277 filings 274 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)